International Journal of Hematology

, Volume 79, Issue 4, pp 377–383 | Cite as

Lentiviral gp34/OX40L Gene Transfer into Dendritic Cells Facilitates Alloreactive CD4+ T-Cell Response In Vitro

  • Masayuki Kobayashi
  • Akifumi Takaori-Kondo
  • Keiko Fukunaga
  • Hiroyuki Miyoshi
  • Takashi Uchiyamaa


Gene-modified dendritic cells (DCs) are promising targets for cancer immunotherapy. In this study, we demonstrated that lentiviral transduction of DCs with the gp34/OX40L gene, one of the costimulatory molecules, facilitates alloreactive CD4+ T-cell response in vitro. We achieved a 20% to 40% efficiency of gp34/OX40L gene transfer into DCs by the lentiviral vector, and lentiviral gp34/OX40L gene transfer did not alter the surface phenotype of either immature or mature DCs, suggesting that expression of gp34/OX40L did not induce the maturation of immature DCs and that gp34/OX40L—transduced DCs could fully differentiate into mature DCs. gp34/OX40L gene transfer facilitated an allogeneic CD4+ T-cell response in vitro by mature DCs but not by immature DCs. Dose escalation of the transgene induced an increasing amount of gp34/OX40L expression, leading to an increasing level of up-regulation of the allogeneic CD4+ T-cell response. The addition of anti-gp34 monoclonal antibody totally abrogated this up-regulation. These results suggest that this facilitation of allogeneic CD4+ T-cell response is specifically dependent on gp34/OX40L expressed on transduced DCs. Taken together, our findings show that gp34/OX40L plays an important role in allogeneic CD4+ T-cell activation by DCs and that lentiviral gp34/OX40L gene transfer into DCs may be a useful strategy for cancer immunotherapy.

Key words

Lentiviral vector OX40/OX40L Gene-modified dendritic cells Allogeneic T-cell response Flow cytometric analysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity.Nature. 1998;392:245–252.CrossRefPubMedGoogle Scholar
  2. 2.
    Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus—positive Hodgkin’s lymphoma.Int J Cancer. 2001;93:706–713.CrossRefPubMedGoogle Scholar
  3. 3.
    Naldini L,Blomer U, Gage FH,Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the trans-gene in adult rat brains injected with a lentiviral vector.Proc Natl Acad Sci U S A. 1996;93:11382–11388.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.Science. 1996;272:263–267.CrossRefGoogle Scholar
  5. 5.
    Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.Proc Natl Acad Sci U S A. 1997;94:10319–10323.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors.Science. 1999;283:682–686.CrossRefPubMedGoogle Scholar
  7. 7.
    Chinnasamy N, Chinnasamy D, Toso JF, et al. Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors.Hum Gene Ther. 2000;11:1901–1909.CrossRefPubMedGoogle Scholar
  8. 8.
    Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector.J Virol. 1998;72:8150–8157.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system.J Virol. 1998;72:8463–8471.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cyto-toxic T-lymphocyte response in vitro.Blood. 2000;96:1327–1333.PubMedGoogle Scholar
  11. 11.
    Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes.J Exp Med. 1996;183:725–729.CrossRefPubMedGoogle Scholar
  12. 12.
    Stripecke R, Cardoso AA, Pepper KA, et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses.Blood. 2000;96:1317–1326.PubMedGoogle Scholar
  13. 13.
    Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.Blood. 2000;96:91–99.PubMedGoogle Scholar
  14. 14.
    Baum PR, Gayle RB 3rd, Ramsdell F, et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34.EMBO J. 1994;13:3992–4001.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.J Exp Med. 1994; 180:757–762.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Imura A, Hori T, Imada K, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells.J Exp Med. 1996;183:2185–2195.CrossRefGoogle Scholar
  17. 17.
    Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.Blood. 1995;85:3378–3404.Google Scholar
  18. 18.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.Cell. 1994;76:959–962.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes.Blood. 2001;97:114–121.CrossRefGoogle Scholar
  20. 20.
    Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells.J Immunol. 1997;159:3838–3848.PubMedGoogle Scholar
  21. 21.
    Murata K, Ishii N, Takano H, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand.J Exp Med. 2000;191:365–374.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chen AI, McAdam AJ, Buhlmann JE, et al. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.Immunity.. 1999;11:689–698.CrossRefPubMedGoogle Scholar
  23. 23.
    Imura A, Hori T, Imada K, et al. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration.Blood. 1997;89:2951–2958.PubMedGoogle Scholar
  24. 24.
    Matsumura Y, Hori T, Kawamata S, Imura A, Uchiyama T. Intra-cellular signaling of gp34, the OX40 ligand: induction of c-jun and c-fos mRNA expression through gp34 upon binding of its receptor, OX40.J Immunol. 1999;163:3007–3011.PubMedGoogle Scholar
  25. 25.
    Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.Cancer Res. 1996;56:5672–5677.PubMedGoogle Scholar
  26. 26.
    Ukyo N, Hori T, Yanagita S, Ishikawa T, Uchiyama T. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.Immunology. 2003;109:226–231.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Schroers R, Sinha I, Segall H, et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system.Mol Ther. 2000;1:171–179.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Masayuki Kobayashi
    • 1
  • Akifumi Takaori-Kondo
    • 1
  • Keiko Fukunaga
    • 1
  • Hiroyuki Miyoshi
    • 2
  • Takashi Uchiyamaa
    • 1
  1. 1.Department of Hematology and Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Subteam for Manipulation of Cell FateBioResource Center, RIKEN Tsukuba InstituteTsukuba, IbaragiJapan

Personalised recommendations